| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 122,060 | 85,239 | 41,143 | 91,592 |
| Research and development | 22,468 | 23,373 | 27,432 | 29,827 |
| Selling, general and administrative | 21,908 | 16,795 | 24,260 | 36,113 |
| Restructuring, net | 2,200 | -250 | 18,559 | 16 |
| Total costs and expenses | 46,576 | 39,918 | 70,251 | 65,956 |
| Income from operations | 75,484 | 45,321 | -29,108 | 25,636 |
| Interest expense and other financing costs | 8,434 | 8,356 | 8,070 | 9,419 |
| Interest and investment income | 930 | 818 | 869 | 1,152 |
| Other | 40 | 39 | 37 | - |
| Other income (expense), net | -7,464 | -7,499 | -7,164 | -8,267 |
| Income before income taxes | 68,020 | 37,822 | -36,272 | 17,369 |
| Income tax expense | 27,940 | 14,223 | 1,114 | 13,723 |
| Net income (loss), including portion attributable to noncontrolling interest | - | - | - | 3,646 |
| Net income (loss) | 40,080 | 23,599 | -37,386 | 3,646 |
| Earnings per share, basic | 0.25 | 0.15 | -0.23 | 0.02 |
| Earnings per share, diluted | 0.23 | 0.14 | -0.23 | 0.02 |
| Weighted average number of shares outstanding, basic | 162,215,000 | 161,723,000 | 160,974,000 | 159,706,000 |
| Weighted average number of shares outstanding, diluted | 177,764,000 | 176,837,000 | 160,974,000 | 160,232,000 |
IRONWOOD PHARMACEUTICALS INC (IRWD)
IRONWOOD PHARMACEUTICALS INC (IRWD)